Psoriasis is a chronic, inflammatory, immune-mediated disease, characterized by erythematous scaly plaques occurring in about 2-3% of the population. TNF- α plays a role not only in the inflammatory cascade but also in body weight homeostasis which could be disrupted by TNF-α inhibitors, such as adalimumab, infliximab, and etanercept, used for treatment of moderate-severe psoriasis. The goal of this study is to determine the association between the use of TNF-α inhibitors and weight gain in patients with plaque psoriasis based on available clinical trials. This article is protected by copyright. All rights reserved.